Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Bombesin labeled · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Bombesin (68Ga) labeled (BAY86-7548) | DRUG | Cancer patients, single intravenous bolus injection of 140 MBq BAY86-7548 on day one of the treatment period, PET/CT |
Inclusion Criteria: * Healthy volunteers: * males, \>/=50 and \</= 65 years of age * Cancer patients: * males \>/= 45 years of age * Patients had an MRI of the prostate and/or a positive choline or acetate PET/CT for diagnosis (Note: MRI, choline and acetate PET/CT are optional for primary ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Hologic, Inc. | HOLX | 1 | N/A | Undisclosed |
| Intelligent Bio Solutions Inc. | INBS | 1 | - | Undisclosed |
| HeartFlow, Inc. | HTFL | 1 | N/A | Rosuvastatin |
| GE Healthcare Technologies Inc. | GEHC | 2 | N/A | Undisclosed |
Bombesin labeled is an investigational small molecule being studied for use in diagnostic imaging. It is being evaluated as a PET/CT imaging agent for radiation dosimetry, plasma pharmacokinetics, biodistribution, safety, tolerability, and diagnostic performance in patients with prostate cancer and healthy volunteers.
Bombesin labeled is being developed by Lantheus Holdings, Inc., which trades under the ticker LNTH. The company is conducting clinical research on this diagnostic imaging agent.
Bombesin labeled is in Phase 1 clinical development. It is an investigational agent and has not been approved by regulatory authorities. The Phase 1 trial has been completed.
Bombesin labeled has one completed Phase 1 trial, NCT01205321, which evaluated PET/CT imaging for radiation dosimetry, plasma pharmacokinetics, biodistribution, safety, tolerability, and diagnostic performance in patients with prostate cancer and healthy volunteers. The trial enrolled 19 participants.
Yes, Bombesin labeled is also known as BAY86-7548. The clinical trial NCT01205321 used the name BAY86-7548 to refer to this investigational diagnostic imaging agent.